Dr. Andrea Engel joined Evonik’s Health Care business line in 2013 and is currently Director Research & Development.
The team focuses on the development and analytics of new oral and parenteral platform technologies for the pharma and food industry as well as the development of cell culture media. One of the main research areas lies in the formulation and bioavailability enhancement of poorly bioavailable drugs and biopharmaceuticals.
Before taking over the current position she held a position as laboratory head and project manager in Innovation Management at Evonik where she has gained experience in developing complex oral and parenteral dosage forms and handling of highly potent active pharmaceutical ingredients.
She received her degree in pharmacy from the University of Frankfurt am Main and her Ph.D. in pharmaceutical technology and biopharmacy from the University of Muenster where she has specialized on the development of drug delivery systems based on bioabsorbable nanoparticles for cancer treatment.
Moreover, she has authored several research papers and patent applications.